. Author manuscript; available in PMC: 2018 Aug 13.

Published in final edited form as: Expert Opin Emerg Drugs. 2018 Apr 4;23(2):123–133. doi: 10.1080/14728214.2018.1459563

Table 3:

PARP inhibitors in clinical practice or in late-phase clinical trials

Drug Name	Manufacturer	FDA Approved Indications
Niraparib	Tesaro	Maintenance in recurrent ovarian carcinoma, biomarker-unselected
Rucaparib	Clovis Oncology	3^rd line treatment of BRCA-deficient ovarian carcinoma
Olaparib	Astra Zeneca	4th line treatment of BRCA-deficient ovarian carcinoma, Priority Review for maintenance therapy in ovarian carcinoma Priority review for 3^rd line treatment of BRCA+ metastatic breast cancer
Drug Name	Manufacturer	Late-Phase Clinical Trials
Niraparib	Tesaro/Janssen Biotech	Phase 3 prostate cancer trials being planned
Rucaparib	Clovis Oncology	In phase 3 trials (TRITON3) for HR-deficient metastatic CRPC
Olaparib	Astra Zeneca	In phase 3 trials (PROFOUND) for HR-deficient metastatic CRPC
Veliparib	AbbVie	In phase 3 trials for ovarian, triple negative breast, and lung cancer
Talazoparib	Pfizer	In phase 3 trials for BRCA-positive breast carcinoma